## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
rusinington,	D.O.	20040	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hesslein Robert W.					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Voyager Therapeutics, Inc. [ VYGR ]									elationship of ck all applica Director	able)	g Pers	10% Ov	o Issuer % Owner ner (specify	
(Last) (First) (Middle) C/O VOYAGER THERAPEUTICS, INC. 75 SIDNEY STREET					01	3. Date of Earliest Transaction (Month/Day/Year) 01/13/2022									Senio	r VP & C	below) General Counsel		1
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Date	ate   E lonth/Day/Year)   if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction   Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5. Amoun Securities Beneficia Owned Fo	s lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	Transacti (Instr. 3 a	ion(s)			(1115ti. 4)
Common Stock 0				01/13	3/2022			A		20,000 <sup>(1)</sup> A		\$0	130,056			D			
			Table II - I				urities Is, warr								Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ransac ode (li		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Ex Expiration (Month/Da	Date	of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	e derivativ Securitie Beneficia Owned Followin Reported	e (Ces Fally Ces (Ces (Ces (Ces (Ces (Ces (Ces (Ces	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)		Date Exercisabl		xpiration ate	Title	OI N	mount r umber f Shares		Transacti (Instr. 4)	ui(s)		
Stock Option (Right to Buy)	\$2.85	01/13/2022			A		120,000		(2)	0	1/13/2032	Comm		20,000	\$0	120,000		D	

## **Explanation of Responses:**

- 1. Consists of shares of common stock issuable under an aggregate of 20,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
- 2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 13, 2022. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

/s/ Robert W. Hesslein

01/18/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.